Trimedat

General characteristics. Structure:

Active agent: trimebutina maleate of 100 mg; 200 mg

Excipients: lactose; silicon dioxide colloid; talc; corn starch; magnesium stearate.

Pharmacological properties:

Pharmacodynamics. Trimebutin, affecting enkefalinergichesky system of intestines, is the regulator of its vermicular movement. Having affinity to receptors of excitement and suppression, has a promoting effect at hypokinetic conditions of smooth muscles of intestines and spasmolytic — at hyperkinetic.
Drug works throughout a GIT, reduces a gullet sphincter tone, promotes gastric emptying and strengthening of a vermicular movement of intestines, and also promotes response of smooth muscles of a large intestine to food irritants. Trimebutin recovers normal physiological activity of muscles of intestines at various gastrointestinal diseases connected with motility disturbances.

Pharmacokinetics. After intake тримебутин it is quickly soaked up from a GIT. Tmax in a blood plasma is 1–2 h. Bioavailability makes 4–6%. Vd — 88 l.
Extent of linkng with proteins of plasma low — about 5%. Trimebutin in insignificant degree gets through a placental barrier.

Metabolism and removal. Trimebutin biotransformirutsya in a liver and is brought with urine preferential in the form of metabolites (about 70% during the first 24 h). T1/2 is about 12 h.

Indications to use:

- motor frustration at functional gastrointestinal diseases, a gastroesophageal reflux disease, dispeptic frustration at gastroduodenal diseases (an abdominal pain, digestion disturbance, nausea, vomiting), a syndrome of the angry intestines (the functional gastrointestinal disease which is shown, in particular, pains and gripes in an abdominal cavity, enterospasms, a meteorism, diarrhea and/or a lock);

- postoperative paralytic intestinal impassability, preparation for radiological and endoscopic researches GITs;

- use for children — the dispepsichesky frustration connected with disturbance of motility of a GIT.

Route of administration and doses:

Inside.
To adults and children since 12 years: on 100–200 mg 3 times a day. For the prevention of a recurrence of a syndrome of the angry intestines after treated during remission it is recommended to continue administration of drug in a dose of 300 mg/days during 12 weeks.
Children of 5-12 years: on 50 mg 3 times a day.
Children of 3-5 years: on 25 mg 3 times a day.

Features of use:

The course of treatment of a syndrome of the angry intestines during the acute period in a dose of 600 mg/days during 4 weeks and continuation of treatment after the conducted course in a dose of 300 mg/days during 12 weeks allows to avoid a disease recurrence.

Side effects:

Seldom — skin reactions.

Interaction with other medicines:

Medicinal interaction of the drug Trimedat® is not described.

Contraindications:

- hypersensitivity to the components which are a part of drug;
- children's age up to 3 years — for this dosage form.

Use at pregnancy and feeding by a breast
It is not recommended to use drug in the I trimester of pregnancy.
It is not recommended to appoint Trimedat® in the period of a lactation, due to the lack of the reliable clinical data confirming safety of use of drug during this period.

In pilot studies data on teratogenecity and embriotoxity of drug are not revealed.

Overdose:

So far about cases of overdose of the drug Trimedat® it was not reported.

Storage conditions:

At a temperature not above 25 °C.
To store in the place, unavailable to children.

Issue conditions:

Without recipe

Packaging:

Tablets, 100 mg and 200 mg. In packagings of planimetric PVC, cell from a film, and the printing aluminum foil varnished on 10 pieces. In a pack from a cardboard bandbox 1, 2 or 3 packagings.